A 7-valent pneumococcal conjugate vaccine has demonstrated an impact on pneumococcal
bacteremia in the immunized pediatric population, extending to nonimmunized adults via …

Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease
in children worldwide. Although a pneumococcal polysaccharide vaccine has been …

In contrast to earlier pneumococcal vaccines, conjugate vaccines hold promise for reducing
pneumococcal morbidity and mortality in infants and young children. The first commercially …

Infections caused by Streptococcus pneumoniae are a major cause of morbidity and
mortality in the pediatric population worldwide. Development of increasing resistance to …

Streptococcus pneumoniae is a major cause of pneumonia, meningitis, and otitis media and
is responsible for disease in young children, the elderly, and immunocompromised …

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and
bacterial meningitis. Although effective antimicrobial drugs have reduced case fatality, the …

Streptococcus pneumoniae-related infections have a major global impact on healthcare,
especially in the developing world, and are considered the number one vaccine-preventable …

Since 2000, when the first pneumococcal conjugate vaccine was introduced into routine use
in the USA, it has had a substantial impact on invasive pneumococcal disease both in the …

Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and
acute otitis media in children and adults worldwide. According to World Health Organization …

The universal immunization of infants and toddlers with pneumococcal conjugate vaccine
(PCV) in the United States beginning in 2000 heralded a new era for pneumococcal disease …